comparemela.com

Ambrx Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

J&J gains another bispecific antibody with $1 25B skin drug buy

BioPharma

Abbvie rinvoqRegeneron dupixentAmbrx biopharmaNovo holdingsBoehringer ingelheimDive briefYellow jersey therapeuticsCandice long

J&J scratches AD itch by acquiring experimental eczema antibody for $1 25B

J&J will pick up Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion to acquire all assets related to NM26.

David urechDavid leeAmbrx biopharmaDrug administrationJohnson innovative medicineYellow jersey therapeuticsNumab therapeutics

Johnson & Johnson plans $850M Proteologix acquisition

The play for the California biotech will expand the company's dermatology portfolio.

La jollaUnited statesDavid leeDavid shenAmbrx biopharmaProteologix incNew brunswick based

Biopharma M&A surges year over year in Q1

M&amp;amp;amp;A dealmaking in the pharmaceutical and biotechnology industry is on the rise, signaling increased confidence and a focus on growth amid challenges. Read more here.

Alison labyaAmbrx biopharmaNovo holdingFusion pharmaceuticalsNovo nordiskGilead scienceCymabay therapeuticsData business fundamentals analyst alison labyaInflation reduction actBiopharmaceutical industry

Biopharma M&A activity jumped 71% in Q1 2024

Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking.

Alison labyaAmbrx biopharmaNovo holdingsGilead sciencesFusion pharmaceuticalsNovo nordiskBig pharmaInflation reduction actNovo holdingsCymabay therapeuticsFederal trade commission

vimarsana © 2020. All Rights Reserved.